MedTrace Logo

Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss

NCT00471510 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2008-05-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of three doses of topical NEOSH101 applied once-daily (qd) for 16 weeks in men with thinning hair in the top and center of the scalp (Norwood/Hamilton grades III-IV androgenetic alopecia). Four equally sized treatment groups (35 men each) will receive either NEOSH101 0.5%, NEOSH101 1.0%, NEOSH101 2.0% or placebo. A 12-week observation period will follow the treatment period.

Conditions

Interventions

DRUG

tetrapeptide aldehyde proteasome inhibitor (NEOSH101)

Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks

Sponsors & Collaborators

  • Neosil, Inc.

    lead INDUSTRY

Principal Investigators

  • Johannes Gassmueller, MD · bioskin Institute for Dermatological Research and Development GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-02-29

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00471510 on ClinicalTrials.gov